Galleri in the Medicare Population

Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity

This multi-center comparative, prospective, cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri^®, a blood-based multi-cancer early detection (MCED) test. The study will seek to enroll approximately 20% of the study participants from under-represented minority populations (e.g., racial / ethnic minority groups, socioeconomically disadvantaged populations, rural populations).

The study will enroll approximately 50,000 participants aged 50 and older with Medicare coverage who will receive Galleri in addition to usual care as well as a passively-enrolled contemporaneous comparator cohort of approximately 50,000 Medicare beneficiaries who receive usual care without MCED screening.